Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-Infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO.

Trial Profile

Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-Infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jul 2013

At a glance

  • Drugs Enfuvirtide (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO; APOLLO-ANRS 130
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Nov 2012 Results published in Antimicrobial Agents and Chemotherapy.
    • 19 Nov 2012 Primary endpoint 'Immunological-response-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top